Cooper Companies, Total Revenue Over Time
| COO Stock | USD 102.40 1.60 1.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cooper Companies, Performance and Cooper Companies, Correlation. Cooper |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cooper Companies,. If investors know Cooper will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cooper Companies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.209 | Earnings Share 1.79 | Revenue Per Share 19.14 | Quarterly Revenue Growth 0.078 | Return On Assets 0.0339 |
The market value of Cooper Companies, is measured differently than its book value, which is the value of Cooper that is recorded on the company's balance sheet. Investors also form their own opinion of Cooper Companies,'s value that differs from its market value or its book value, called intrinsic value, which is Cooper Companies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cooper Companies,'s market value can be influenced by many factors that don't directly affect Cooper Companies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cooper Companies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cooper Companies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cooper Companies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Revenue Analysis
Compare Cooper Companies, and related stocks such as West Pharmaceutical, Hologic, and ICU Medical Total Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WST | 190.1 M | 1.2 B | 1.3 B | 1.4 B | 1.4 B | 1.4 B | 1.5 B | 1.6 B | 1.7 B | 1.8 B | 2.1 B | 2.8 B | 2.9 B | 2.9 B | 3.1 B |
| HOLX | 11.4 M | 2 B | 2.5 B | 2.5 B | 2.7 B | 2.8 B | 3.1 B | 3.2 B | 3.4 B | 3.8 B | 5.6 B | 4.9 B | 4 B | 4 B | 4.2 B |
| ICUI | 7.5 M | 302.2 M | 316.9 M | 313.7 M | 309.3 M | 341.7 M | 379.4 M | 1.3 B | 1.4 B | 1.3 B | 1.3 B | 1.3 B | 2.3 B | 2.3 B | 2.4 B |
| HAE | 157.3 M | 727.8 M | 892 M | 938.5 M | 910.4 M | 909.7 M | 886.1 M | 903.9 M | 967.6 M | 988.5 M | 870.5 M | 993.2 M | 1.2 B | 1.3 B | 1.4 B |
| TFX | 171.8 M | 1.5 B | 1.6 B | 1.7 B | 1.8 B | 1.8 B | 1.9 B | 2.1 B | 2.4 B | 2.6 B | 2.5 B | 2.8 B | 2.8 B | 3 B | 1.8 B |
| RMD | 7.7 M | 1.4 B | 1.5 B | 1.6 B | 1.7 B | 1.8 B | 2.1 B | 2.3 B | 2.6 B | 3 B | 3.2 B | 3.6 B | 4.2 B | 4.7 B | 4.9 B |
| BDX | 1.1 B | 7.7 B | 8.1 B | 8.4 B | 10.3 B | 12.5 B | 12.1 B | 16 B | 17.3 B | 17.1 B | 20.2 B | 18.9 B | 19.4 B | 20.2 B | 21.2 B |
| BLCO | 3.7 B | 3.7 B | 3.7 B | 3.7 B | 3.7 B | 3.7 B | 3.7 B | 3.7 B | 3.7 B | 3.8 B | 3.4 B | 3.8 B | 3.8 B | 4.1 B | 4.1 B |
| RGEN | 3.6 M | 23.5 B | 62.3 M | 68.2 M | 63.5 M | 83.5 M | 104.5 M | 141.2 M | 194 M | 270.2 M | 366.3 M | 670.5 M | 801.5 M | 638.8 M | 768 M |
| MMSI | 1.4 M | 359.4 M | 394.3 M | 449 M | 509.7 M | 542.1 M | 603.8 M | 727.9 M | 882.8 M | 994.9 M | 963.9 M | 1.1 B | 1.2 B | 1.3 B | 1.3 B |
| ANGO | 23.4 M | 221.8 M | 342 M | 354.5 M | 357 M | 353.7 M | 349.6 M | 344.3 M | 359.5 M | 264.2 M | 291 M | 316.2 M | 338.8 M | 303.9 M | 246.7 M |
| ATR | 370.3 M | 2.3 B | 2.3 B | 2.5 B | 2.6 B | 2.3 B | 2.3 B | 2.5 B | 2.8 B | 2.9 B | 2.9 B | 3.2 B | 3.3 B | 3.5 B | 1.9 B |
| NVST | 2.7 B | 2.7 B | 2.7 B | 2.7 B | 2.7 B | 2.7 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 2.3 B | 2.5 B | 2.6 B | 2.6 B | 2.1 B |
Cooper Companies, and related stocks such as West Pharmaceutical, Hologic, and ICU Medical Total Revenue description
Total revenue comprises all receipts Cooper Companies, generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.My Equities
My Current Equities and Potential Positions
| The Cooper Companies, | COO |
| Classification | Medical Equipment |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 102.4
Check out Cooper Companies, Performance and Cooper Companies, Correlation. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Cooper Companies, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.